Universe Pharmaceuticals (UPC) Total Non-Current Liabilities (2024)
Universe Pharmaceuticals' (UPC) quarterly Total Non-Current Liabilities came in at $2.1 billion in Q3 2024.
Universe Pharmaceuticals (UPC) Total Non-Current Liabilities (2024) Analysis & Trends
Universe Pharmaceuticals has disclosed Total Non-Current Liabilities across 1 years of filings, most recently posting $2.1 billion for Q3 2024.
- Total Non-Current Liabilities for Q3 2024 came in at $2.1 billion, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $2.1 billion (changed N/A YoY), and the FY2024 annual result was $2.1 billion, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $2.1 billion for Q3 2024 at Universe Pharmaceuticals.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.1 billion in Q3 2024 to a low of $2.1 billion in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Universe Pharmaceuticals | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.14 Bn |